| Literature DB >> 28786499 |
R Knobler1, P Moinzadeh2, N Hunzelmann2, A Kreuter3, A Cozzio4, L Mouthon5, M Cutolo6, F Rongioletti7, C P Denton8, L Rudnicka9, L A Frasin10, V Smith11, A Gabrielli12, E Aberer13, M Bagot14, G Bali15, J Bouaziz14, A Braae Olesen16, I Foeldvari17, C Frances18, A Jalili19, U Just1, V Kähäri20, S Kárpáti15, K Kofoed21, D Krasowska22, M Olszewska9, C Orteu23, J Panelius24, A Parodi25, A Petit14, P Quaglino26, A Ranki27, J M Sanchez Schmidt28, J Seneschal29, A Skrok9, M Sticherling30, C Sunderkötter31, A Taieb29, A Tanew1, P Wolf13, M Worm32, N J Wutte13, T Krieg2.
Abstract
The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).Entities:
Mesh：
Year: 2017 PMID： 28786499 DOI： 10.1111/jdv.14466
Source DB: PubMed Journal: J Eur Acad Dermatol Venereol ISSN： 0926-9959 Impact factor: 6.166